{"classes":[{"categories":[{"measurements":[{"comment":"Data for OS was not planned to be summarized per SAP. Individual data was collected but not reported as it would lead to re-identification of participants.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"Overall survival (OS) was the time from the first date of the study intervention to the date of death due to any cause. Participants not known to have died are censored on the date of last known alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"MEDIAN","populationDescription":"SAS included all enrolled participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"From the date of first dose until death due to any cause or censoring date (maximum of 65.1 weeks of treatment)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}